$46.97
3.22% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US36870G1058
Symbol
IRON
Sector
Industry

Gemini Therapeutics Inc Stock price

$48.53
-5.80 10.68% 1M
-2.67 5.21% 6M
-14.87 23.45% YTD
+16.50 51.49% 1Y
+34.23 239.37% 3Y
-54.47 52.88% 5Y
-54.47 52.88% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.38 2.93%
ISIN
US36870G1058
Symbol
IRON
Sector
Industry

Key metrics

Market capitalization $1.68b
Enterprise Value $1.22b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.27
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-129.72m
Free Cash Flow (TTM) Free Cash Flow $-94.43m
Cash position $489.88m
EPS (TTM) EPS $-3.99
P/E forward negative
Short interest 7.21%
Show more

Is Gemini Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Gemini Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Gemini Therapeutics Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Gemini Therapeutics Inc forecast:

Buy
100%

Financial data from Gemini Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.16 0.16
30% 30%
-
-0.16 -0.16
30% 30%
-
- Selling and Administrative Expenses 33 33
53% 53%
-
- Research and Development Expense 97 97
40% 40%
-
-130 -130
43% 43%
-
- Depreciation and Amortization 0.16 0.16
30% 30%
-
EBIT (Operating Income) EBIT -130 -130
42% 42%
-
Net Profit -109 -109
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gemini Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gemini Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a recap of recent pr...
Neutral
GlobeNewsWire
about one month ago
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences:

Company Profile

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO John Quisel
Employees 84
Founded 2017
Website www.discmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today